Detection of Epstein–Barr virus DNA in peripheral blood is associated with the development of bronchiolitis obliterans syndrome after lung transplantation☆
Section snippets
Background
Lung transplantation is a therapy for end-stage lung disease. However, lung transplantation is complicated by chronic organ dysfunction termed bronchiolitis obliterans syndrome (BOS) (according to clinical criteria) which develops in about 50% of LTR until 5 years after transplantation. It is the most important risk factor for five-year mortality.1 Repeated acute rejection is a risk factor for BOS and several studies suggest that cytomegalovirus (CMV) and respiratory virus infections play a
Study design
A prospective cohort study was performed in lung and heart–lung transplant recipients (called LTR) transplanted between 1988 and 2006 who were followed up in the outpatient clinic of Medizinische Hochschule Hannover. Inclusion criteria: adult LTR; informed consent to participate in the study; at least one outpatient clinic visit during the study period (October 31, 2005 to April 28, 2006). 16 LTR who refused consent and three who had no blood specimen examined for EBV DNA were excluded (Fig. 1
Results
385 LTR were included and visited the outpatient clinics 769 times during the study period (6 months; median one visit per patient, range 1–9). Patient demographics are shown in Table 1.
86 LTR (22.3%) had been diagnosed with BOS before study entry. Seven LTR were first diagnosed with BOS at the time of the study visit. 38 (13.0%) of the remaining 292 LTR developed BOS after inclusion in the study. 5 LTR received a retransplantation. 31 LTR died during the follow-up period of whom 22 had EBV DNA
Discussion
This is so far the largest cohort of LTR studied to address the question whether EBV, CMV and HAdV contribute to the development of BOS. EBV DNA, HAdV DNA and CMV pp65 antigen were detected in the blood of, respectively, 52.5%, 2.6% and 4.9% of LTR at least once. The frequency of EBV DNA detection was comparable to that found in smaller cohorts of LTR.13, 14, 15 The frequency of CMV pp65 antigen and HAdV DNA detection was lower than reported by others16, 17 possibly due to different observation
Conflict of interest
None.
Ethical approval
The study was approved by the review board of Medizinische Hochschule Hannover.
Acknowledgements
The study was supported from core funding of Medizinische Hochschule Hannover. The excellent technical assistance of M. Wehrhane and S. Hübner is acknowledged. We thank M. Zühlsdorf, M. Dierich and N. Hesse for help with data acquisition.
References (32)
- et al.
Risk factors for bronchiolitis obliterans: a systematic review of recent publications
J Heart Lung Transplant
(2002) - et al.
Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria
J Heart Lung Transplant
(2002) Cytomegalovirus and lung transplantation
Am J Transplant
(2004)- et al.
Eleven years on: a clinical update of key areas of the 1996 lung allograft rejection working formulation
J Heart Lung Transplant
(2007) - et al.
Association between elevated whole blood Epstein–Barr virus (EBV)-encoded RNA EBV polymerase chain reaction and reduced incidence of acute lung allograft rejection
J Heart Lung Transplant
(2007) - et al.
A surveillance study of adenovirus infection in adult solid organ transplant recipients
Am J Transplant
(2005) - et al.
Human herpesvirus 6 in bronchalveolar lavage fluid after lung transplantation: a risk factor for bronchiolitis obliterans syndrome?
Am J Transplant
(2005) - et al.
Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection
Leuk Res
(1996) - et al.
Interleukin-12 expression in B cells by transformation with Epstein–Barr virus
Biochem Biophys Res Commun
(1998) - et al.
Upregulation of chemokines in bronchoalveolar lavage fluid as a predictive marker of post-transplant airway obliteration
J Heart Lung Transplant
(2002)
Bronchoalveolar lavage cytokine profile in a cohort of lung transplant recipients: a predictive role of interleukin-12 with respect to onset of bronchiolitis obliterans syndrome
J Heart Lung Transplant
Respiratory viruses and chronic rejection in lung transplant recipients
J Heart Lung Transplant
Clinical impact of community-acquired respiratory viruses on bronchiolitis obliterans after lung transplant
Am J Transplant
Mechanisms of airway obliteration after lung transplantation
Proc Am Thorac Soc
Bronchiolitis obliterans and lung transplantation: evidence for an infectious etiology
Semin Respir Infect
Adenovirus infections in transplant recipients
Clin Infect Dis
Cited by (35)
T-lymphocyte subsets in lung transplant recipients: Association between nadir CD4 T-cell count and viral infections after transplantation
2015, Journal of Clinical VirologyCitation Excerpt :Thus, both opportunistic (OI) and community-acquired (CAI) infections remain a major cause of morbidity and mortality in LTR. In addition, the role of viral infections in favoring the occurrence of chronic lung allograft dysfunction has been suggested [2,3]. Therefore, early detection and appropriate treatment of infections is mandatory to improve the outcome in these patients.
Detection of cytomegalovirus (CMV) by real-time PCR in fecal samples for the non-invasive diagnosis of CMV intestinal disease
2014, Journal of Clinical VirologyCitation Excerpt :Histopathological and clinical data were retrieved from medical records. In addition, we analyzed the results of CMV pp65 antigenemia testing (performed as described previously [19]) from peripheral blood obtained within 10 days before or after biopsy sampling. CMV antigenemia data were available for 53 out of 66 patients, obtained in median at day 0 (range −10 to +10) after the biopsy.
Lung transplantation and donor lung repair
2023, Bronchoalveolar Lavage in Basic Research and Clinical MedicineScreening and Management of PTLD
2023, TransplantationEvaluation of host cellular responses to Epstein–Barr virus (EBV) in adult lung transplant patients with EBV-associated diseases
2023, Journal of Medical Virology
- ☆
The study was registered at www.clinicaltrials.gov with the number NCT00701922.